Clinical Manifestations and Treatment Challenges in Infants and Children With Classic Congenital Adrenal Hyperplasia Due to 21-Hydroxylase Deficiency - Top-Institutions - MDSpire

Clinical Manifestations and Treatment Challenges in Infants and Children With Classic Congenital Adrenal Hyperplasia Due to 21-Hydroxylase Deficiency

  • By

  • Natalie J Nokoff

  • Cindy Buchanan

  • Jennifer M Barker

  • January 21, 2025

  • 0 min

Share

Top Institutions in Endocrinology

Brief introduction explaining scope and methodology.

  • #1

    Children's Hospital of Philadelphia
    Children's Hospital of Philadelphia

    Philadelphia, PA

    Key Differentiators

    • Pediatric Endocrinology
    • Genetics
    • Pediatric Surgery

  • #2

    Boston Children's Hospital
    Boston Children's Hospital

    Boston, MA

    Key Differentiators

    • Pediatric Endocrinology
    • Pediatric Surgery
    • Psychosocial Medicine

  • #3

    Cincinnati Children's Hospital Medical Center
    Cincinnati Children's Hospital Medical Center

    Cincinnati, OH

    Key Differentiators

    • Pediatric Endocrinology
    • Genetics
    • Clinical Research

  • #4

    University of California, San Francisco (UCSF) Benioff Children’s Hospital
    University of California, San Francisco (UCSF) Benioff Children’s Hospital

    San Francisco, CA

    Key Differentiators

    • Pediatric Endocrinology
    • Genetics
    • Surgical Reconstruction

Original Source(s)

Clinical Manifestations and Treatment Challenges in Infants and Children With Classic Congenital Adrenal Hyperplasia Due to 21-Hydroxylase Deficiency

  • by Natalie J Nokoff, Cindy Buchanan, Jennifer M Barker

  • January 21, 2025

Related Content

Glucagon-like peptide-1 receptor (GLP-1R) overexpression defines a distinct immunogenetic subset in primary and metastatic thyroid cancer: implications for GLP-1R agonist therapy

Protocol for a randomized controlled trial investigating the effects of sleep extension on body weight and learning in children (More2Sleep)

Gut microbiota and pediatric metabolic dysfunction–associated steatotic liver disease: clinical evidence and therapeutic implications